Dense breast tissue, which is common, and normal (seen in about 40% of women screened), can mask detection of breast cancer on mammography. Ultrasound is known to improve invasive cancer detection after standard mammography in women with dense breasts. Tomosynthesis (3D mammography) improves cancer detection compared to standard mammography. It is not known whether ultrasound would still be of benefit or not after tomosynthesis in women with dense breasts. Opened in December 2015, the purpose of this study is to determine the added cancer detection yield (if any) when screening ultrasound is added to 3D mammography in women with dense breasts. Women will undergo three annual rounds of screening. The cost of the screening ultrasound is covered by the study, funded by the National Cancer Institute and the Pennsylvania Breast Cancer Coalition.

UPMC Shadyside is the first site in Pittsburgh and southwestern Pennsylvania to offer a new F-18 Positron-Emission-Tomography/Computed-Tomography (PET/CT) scan for prostate cancer patients with biochemical recurrence. The novel PET agent F-18 fluciclovine (AxuminTM) was FDA approved in May 2016 and is useful for detecting low prostate-specific antigen (PSA) soft tissue and bone recurrence. This clinical service is the result of close collaboration between the Departments of Radiology and Radiation Oncology. Patients with F-18 PET/CT positive studies may be eligible for targeted radiotherapy: imaging data acquired can be directly retrieved and incorporated for radiation treatment planning.